论文部分内容阅读
随着人类基因组时代的到来,肿瘤病因学和药物基因组学的研究不断深入,研究肿瘤与分子标记物的关系在肿瘤诊断、判断预后及分子靶向治疗上的意义越来越大。目前药物研制的新模式是新基因-新靶点-创新药物出现。子宫肉瘤发病率低,但恶性程度高,治疗效果不理想。诊断现主要依靠组织形态学及免疫组织化学,随着国内外诊断子宫肉瘤分子标记物的逐渐增多,为研究其诊断、治疗及判断预后提供了重要的指导价值。现将目前与子宫肉瘤有关的分子标记物的最新研究进展作一综述。
With the advent of the human genome era, the research on tumor etiology and pharmacogenomics continues to deepen. It is of great significance to study the relationship between tumor and molecular markers in tumor diagnosis, prognosis and molecular targeted therapy. The current new model for drug development is the emergence of new genes - new targets - of innovative drugs. The incidence of uterine sarcoma is low, but the high degree of malignancy, the treatment effect is not satisfactory. Diagnosis is mainly based on histomorphology and immunohistochemistry. With the increasing number of molecular markers for the diagnosis of uterine sarcoma at home and abroad, it provides an important guiding value for studying diagnosis, treatment and prognosis. At present, the current research progress of molecular markers related to uterine sarcoma is reviewed.